SAN DIEGO – A leading investigator put the results in perspective with the currently approved lenalidomide, and the audience questions as to...
SAN DIEGO – Median overall survival among patients with complete responses to CAR-T cell therapy in the JULIET trial has not been reached.
SAN DIEGO – The umbrella trial, sponsored by the Leukemia & Lymphoma Society, harnesses technology to speed genomic results that could...
SAN DIEGO – Median overall survival for patients with complete responses to CAR T-cell therapy was not reached through 19 months of follow-up.
SAN DIEGO – Among patients who had complete remissions, 66% were still in remission at 18 months, overall survival was 70%, and median overall...
SAN DIEGO – Luspatercept also showed promise in a phase 3 trial including adults with beta-thalassemia.
SAN DIEGO – Survival outcomes were nearly identical and adverse events were lower with four versus six cycles of R-CHOP in patients with favorable...
SAN DIEGO – Patients with no history of hematopoietic cell transplant may benefit from consolidation after receiving a CD19-specific CAR T-cell...
From the Journals
The increased risks appear to subside after menopause.
Patients should be diagnosed fast, treated as aggressively as organ health permits, and in clinical trials if possible.